TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Inclusion Criteria:

1. Age ≥18 years old, regardless of gender;

2. Patients with newly diagnosed or persistent primary ITP who have shown inadequateresponse or relapse following first-line corticosteroid treatment with or withoutIVIg;

3. Complete response (PLT > 100 × 10^9/L) achieved after hetrombopag treatment at dosesof 2.5mg-7.5mg per day;

4. Volunteer to participate in clinical research and sign an informed consent form,willing to follow and capable of completing all trial procedures.

Exclusion Criteria:

1. Age>50 years old;

2. Those who are contraindicated to taking aspirin;

3. Previous arterial or venous thrombosis history (including coronary atheroscleroticheart disease, ischemic stroke, deep vein thrombosis or pulmonary embolism, etc.) orclinical symptoms and medical history indicate thrombophilia;

4. Risk factors of cardiovascular diseases such as hypertension, diabetes andhyperlipidemia;

5. Heart disease occurring within the first 3 months of screening, including congestiveheart failure classified as III/IV by the New York Heart Association (NHYA),arrhythmias or myocardial infarction requiring medication, or arrhythmias known toincrease the risk of thrombotic events (such as atrial fibrillation), or prolongedQT interval (QTc) after subject correction (QTc>450 milliseconds, or QTc>480milliseconds in subjects with bundle branch block)

6. Patients currently undergoing anticoagulant therapy or antiplatelet therapy;

7. Female patients receiving estrogen replacement therapy or oral contraceptives;

8. Patients with past or current malignant tumors;

9. Secondary thrombocytopenia, such as myelodysplastic syndrome, immune disorders suchas systemic lupus erythematosus, early aplastic anemia, atypical aplastic anemia,antiphospholipid syndrome, thrombotic thrombocytopenic purpura, and other causes ofthrombocytopenia;

10. The results of bone marrow biopsy during the screening period indicate that the bonemarrow fibrosis MF is ≥ 2 (Thieleja 2005, the European expert consensus bone marrowfibrosis scoring standard), or that bone marrow biopsy suggests the presence ofother primary diseases that can cause thrombocytopenia besides ITP;

11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are three timeshigher than the upper limit of normal values, total bilirubin is three times higherthan the upper limit of normal values, and blood creatinine is 1.5 times higher thanthe upper limit of normal values;

12. Have a history of liver cirrhosis or portal hypertension;

13. Uncontrollable infections;

14. Hepatitis B surface antigen positive or previous history of hepatitis B, and in thepast 3 months, accompanied by HBV-DNA ≥ 2000IU/ML; those with positive hepatitis Cantibody, HCV-RNA positive in the past 3 months;

15. Individuals who test positive for antibodies against human immunodeficiency virus orspecific antibodies against Treponema pallidum;

16. Individuals who are known to be allergic to the drug itself or its excipients;

17. Breastfeeding or pregnant women or female patients planning to conceive during thestudy period; 18）Other situations determined by the researcher as unsuitable forparticipation in this study